Cargando…

Initiation of triple therapy maintenance treatment among patients with COPD in the US

BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends triple therapy (long-acting muscarinic receptor antagonists, long-acting beta-2 agonists, and inhaled corticosteroids) for patients with only the most severe COPD. Data on the proportion of COPD patients on trip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simeone, Jason C, Luthra, Rakesh, Kaila, Shuchita, Pan, Xiaoyun, Bhagnani, Tarun D, Liu, Jieruo, Wilcox, Teresa K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5191839/ https://www.ncbi.nlm.nih.gov/pubmed/28053518 http://dx.doi.org/10.2147/COPD.S122013

Ejemplares similares

Spirometry evaluation to assess performance of a claims-based predictive model identifying patients with undiagnosed COPD
por: Moretz, Chad, et al.
Publicado: (2019)

PRIMUS – Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation
por: Tkacz, Joseph, et al.
Publicado: (2022)

Association between adherence to medications for COPD and medications for other chronic conditions in COPD patients
por: Dhamane, Amol D, et al.
Publicado: (2016)

P1685: PATIENTS’ PREFERENCES FOR MULTIPLE MYELOMA (MM) TREATMENT INITIATION AND DISCONTINUATION IN THE US
por: Binder, Adam F., et al.
Publicado: (2023)

Development and validation of a predictive model to identify patients at risk of severe COPD exacerbations using administrative claims data
por: Annavarapu, Srinivas, et al.
Publicado: (2018)

Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD
por: Dalal, Anand A, et al.
Publicado: (2012)

COPD exacerbation frequency and its association with health care resource utilization and costs
por: Dhamane, Amol D, et al.
Publicado: (2015)

Triple therapy in COPD: understanding the data
por: Suissa, Samy
Publicado: (2023)

Impact of triple therapy on mortality in COPD
por: Soumagne, Thibaud, et al.
Publicado: (2023)

Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population
por: Schwab, Phil, et al.
Publicado: (2017)

Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database
por: Quint, Jennifer K., et al.
Publicado: (2021)

PROMETHEUS: Long-Term Exacerbation and Mortality Benefits of Implementing Single-Inhaler Triple Therapy in the US COPD Population
por: Criner, Gerard, et al.
Publicado: (2023)

Effect of triple therapy in patients with asthma-COPD overlap
por: Ishiura, Yoshihisa, et al.
Publicado: (2019)

Current appraisal of single inhaler triple therapy in COPD
por: Lipworth, Brian, et al.
Publicado: (2018)

Does Timing of Receipt of Appropriate Antimicrobial Therapy Make a Difference Among Patients With Serious Infections Due to Resistant Gram-Negative Pathogens?
por: Berger, Ariel, et al.
Publicado: (2016)

Associations Between Timeliness of Therapy and Clinical and Economic Outcomes Among Patients With Serious Infections Due to Gram-negative Bacteria (GNB): How Much Does Delayed Appropriate Therapy (DAT) Matter?
por: Bonine, Nicole G, et al.
Publicado: (2017)

The use of COPD maintenance therapy following spirometry in General Practice
por: Gottlieb, Vibeke, et al.
Publicado: (2016)

Maintenance Therapy with Nebulizers in Patients with Stable COPD: Need for Reevaluation
por: Terry, Paul D., et al.
Publicado: (2020)

Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment
por: Spielmanns, Marc, et al.
Publicado: (2022)

Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: ATRASH, Shebli, et al.
Publicado: (2021)

Correction to: Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study
por: Atrash, Shebli, et al.
Publicado: (2021)

Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD
por: Kim, Sae Ahm, et al.
Publicado: (2016)

Symptomatic burden of COPD for patients receiving dual or triple therapy
por: Chen, Stephanie, et al.
Publicado: (2018)

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
por: Voorham, Jaco, et al.
Publicado: (2019)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
por: Bourbeau, Jean, et al.
Publicado: (2021)

When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment
por: Cheng, Wen-Chien, et al.
Publicado: (2020)

Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease
por: Sicras Mainar, Antoni, et al.
Publicado: (2019)

Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States
por: Medhekar, Rohan, et al.
Publicado: (2022)

Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma
por: Galaznik, Aaron, et al.
Publicado: (2018)

Carbapenem-resistant Enterobacteriaceae (CRE) or Delayed Appropriate Therapy (DAT)—Does One Affect Outcomes More Than the Other Among Patients With Serious Infections Due to Enterobacteriaceae?
por: Lodise, Thomas, et al.
Publicado: (2017)

The reasons for triple therapy in stable COPD patients in Japanese clinical practice
por: Miyazaki, Masaki, et al.
Publicado: (2015)

The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK
por: Brusselle, Guy, et al.
Publicado: (2015)

The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD
por: Dobler, Claudia C.
Publicado: (2018)

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
por: Vanfleteren, Lowie, et al.
Publicado: (2018)

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
por: Vanfleteren, Lowie E.G.W., et al.
Publicado: (2019)

Preventing clinically important deterioration with single-inhaler triple therapy in COPD
por: Naya, Ian, et al.
Publicado: (2018)

Erratum: Outcome of Inhaler Withdrawal in Patients Receiving Triple Therapy for COPD
Publicado: (2016)

Antimicrobial Resistance or Delayed Appropriate Therapy—Does One Influence Outcomes More Than the Other Among Patients With Serious Infections Due to Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacteriaceae?
por: Lodise, Thomas P, et al.
Publicado: (2019)

DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach
por: Singh, Dave, et al.
Publicado: (2023)

Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population
por: Coutinho, Anna D, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_je2mq120ojs82kc8kvnrh7t5vg